Skip to content

Pharminent

cropped-neurology_aaic_banner_frontpage_2026-07-15-1.png
Primary Menu
  • Home
  • Signal News
  • Biopharma Brief
    • Market Access Intelligence
    • Rare Disease Gene Therapy
    • Oncology
  • Week in Review
    • GLP-1 Competitive Market
    • NeuroMarket Pulse
      • Neurology Interactive Calendar
    • Manufacturing Intelligence
  • Contact
Light/Dark Button
Brief
  • Home
  • Regulatory
  • FDA Expands Market Access, Authorizes New ENDS Products
  • Regulatory

FDA Expands Market Access, Authorizes New ENDS Products

FDA

FDA today authorized the marketing of four Glas electronic nicotine delivery systems (ENDS) through the premarket tobacco product application (PMTA) pathway.

Read full story

pharminent May 5, 2026 (Last updated: May 6, 2026)

FDA

FDA today authorized the marketing of four Glas electronic nicotine delivery systems (ENDS) through the premarket tobacco product application (PMTA) pathway.

Read full story

Sign up to receive free daily digest

Check your inbox or spam folder to confirm your subscription.

Post navigation

Previous: Viridian data lift prospects for thyroid eye disease drug
Next: MSD concludes Terns acquisition to expand CML pipeline

Related Stories

  • Regulatory

Outlook Therapeutics Secures FDA Approval for LYTENAVA

pharminent July 31, 2026
  • Regulatory

Outlook finally claims FDA approval for AMD drug

pharminent July 27, 2026
  • Regulatory

Outlook Therapeutics wins FDA approval for Lytenava in wet AMD

pharminent July 27, 2026
© 2026 All rights reserved. | ReviewNews by AF themes.